To the Editor,

We read with great interest the excellent review entitled "Obstructive sleep apnea and its effects on cardiovascular diseases: a narrative review" by Rivas et al. ([@ref1]) on the cardiovascular comorbidities of patients with obstructive sleep apnea (OSA) published. Indeed, it is increasingly being appreciated that patients with OSA are at a higher risk of coronary artery disease, congestive heart failure, stroke, and atrial fibrillation. Treatment with continuous positive airway pressure (CPAP) reduces these comorbidities ([@ref1]).

A novel important, though less widely used, marker of the severity of OSA is mean platelet volume (MPV), as shown by Varol et al. ([@ref2], [@ref3]) and us ([@ref4]). Again, CPAP treatment has been reported to reduce MPV ([@ref3]). Given its role as a marker of vascular disease and a predictor of acute vascular events ([@ref5]), it appears that MPV also links OSA with cardiovascular disease. Specifically, in patients with OSA, MPV is also associated with atrial fibrillation ([@ref5]).

In conclusion, it is now established that OSA poses patients at an increased risk of cardiovascular disease ([@ref1]). MPV may prove useful as a marker of the latter in patients with OSA ([@ref4], [@ref5]); therefore, it should be more widely utilized for this purpose.
